Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKTX Akari Therapeutics	$1.13 -0.1%	$1.21	$0.85 ▼ $4.40	$36.52M	0.21	31,379 shs	22,571 shs
LYEL Lyell Immunopharma	$10.28 +8.3%	$9.30	$7.65 ▼ $34.90	$140.53M	-0.24	72,382 shs	50,380 shs
NKTX Nkarta	$2.08 +8.3%	$1.81	$1.31 ▼ $7.24	$136.24M	0.7	1.02 million shs	715,246 shs
TLSA Tiziana Life Sciences	$1.62	$1.50	$0.63 ▼ $1.91	$189.29M	-0.05	476,032 shs	197,315 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKTX Akari Therapeutics	+0.44%	+2.16%	+0.53%	-16.54%	-67.85%
LYEL Lyell Immunopharma	+2.71%	-1.86%	+9.21%	+3.15%	-69.58%
NKTX Nkarta	+0.52%	+1.59%	+8.47%	-13.51%	-69.08%
TLSA Tiziana Life Sciences	+4.52%	+9.46%	+3.85%	+39.66%	+90.59%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKTX Akari Therapeutics	2.7521 of 5 stars	3.5	3.0	1.9	3.3	0.0
LYEL Lyell Immunopharma	3.0666 of 5 stars	2.8	5.0	0.9	3.3	1.3
NKTX Nkarta	2.1221 of 5 stars	3.6	0.0	3.1	1.7	0.6
TLSA Tiziana Life Sciences	1.3877 of 5 stars	0.0	5.0	3.1	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKTX Akari Therapeutics	3.00	Buy	$5.00	340.92% Upside
LYEL Lyell Immunopharma	1.50	Reduce	$15.00	45.91% Upside
NKTX Nkarta	3.13	Buy	$14.33	589.10% Upside
TLSA Tiziana Life Sciences	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest AKTX, TLSA, NKTX, and LYEL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/18/2025	AKTX Akari Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$5.00
6/24/2025	LYEL Lyell Immunopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$10.00
6/10/2025	NKTX Nkarta	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $14.00
5/15/2025	NKTX Nkarta	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
5/15/2025	NKTX Nkarta	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00

(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	$0.84 per share	N/A
LYEL Lyell Immunopharma	$60K	2,537.45	N/A	N/A	$26.21 per share	0.39
NKTX Nkarta	N/A	N/A	N/A	N/A	$5.78 per share	N/A
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	$0.04 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKTX Akari Therapeutics	-$19.79M	N/A	0.00	∞	N/A	N/A	-213.59%	-65.60%	8/18/2025 (Estimated)
LYEL Lyell Immunopharma	-$342.99M	-$25.00	N/A	N/A	N/A	-514,649.22%	-73.66%	-60.99%	8/6/2025 (Estimated)
NKTX Nkarta	-$108.79M	-$1.51	N/A	N/A	N/A	N/A	-26.64%	-21.62%	8/12/2025 (Estimated)
TLSA Tiziana Life Sciences	-$11.86M	N/A	0.00	∞	N/A	N/A	N/A	N/A	8/5/2025 (Estimated)

Latest AKTX, TLSA, NKTX, and LYEL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/18/2025	Q2 2025	AKTX Akari Therapeutics	-$0.12	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	NKTX Nkarta	-$0.37	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	LYEL Lyell Immunopharma	-$0.19	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	NKTX Nkarta	-$0.44	-$0.43	+$0.01	-$0.43	N/A	N/A
5/13/2025	Q1 2025	LYEL Lyell Immunopharma	-$3.80	-$3.60	+$0.20	-$0.18	N/A	$0.01 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	N/A
LYEL Lyell Immunopharma	N/A	N/A	N/A	N/A	N/A
NKTX Nkarta	N/A	N/A	N/A	N/A	N/A
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKTX Akari Therapeutics	N/A	0.16	0.16
LYEL Lyell Immunopharma	N/A	7.49	7.49
NKTX Nkarta	N/A	14.48	14.48
TLSA Tiziana Life Sciences	N/A	1.02	1.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKTX Akari Therapeutics	5.06%
LYEL Lyell Immunopharma	66.05%
NKTX Nkarta	80.54%
TLSA Tiziana Life Sciences	N/A

Insider Ownership

Company	Insider Ownership
AKTX Akari Therapeutics	38.10%
LYEL Lyell Immunopharma	22.30%
NKTX Nkarta	8.40%
TLSA Tiziana Life Sciences	39.82%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKTX Akari Therapeutics	9	32.18 million	19.92 million	Not Optionable
LYEL Lyell Immunopharma	270	14.81 million	11.51 million	Optionable
NKTX Nkarta	140	70.96 million	65.00 million	Optionable
TLSA Tiziana Life Sciences	8	116.85 million	70.32 million	Optionable

AKTX, TLSA, NKTX, and LYEL Headlines

Recent News About These Companies

Tiziana Life Sciences reports encouraging results from nasal Alzheimer's treatment

July 21 at 9:28 AM | proactiveinvestors.com

Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient

July 21 at 7:00 AM | globenewswire.com

Tiziana Life Sciences Ltd (TLSA) - Yahoo Finance

July 11, 2025 | finance.yahoo.com

Tiziana Life Sciences (NASDAQ:TLSA) Stock Price Down 2.6% - Here's Why

July 9, 2025 | marketbeat.com

Tiziana: Scope Of Foralumab Goes Beyond That Of Multiple Sclerosis Targeting

June 13, 2025 | seekingalpha.com

Tiziana Life Sciences expands Phase 2 MS trial to fifth site, commences patient dosing

June 13, 2025 | proactiveinvestors.com

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center

June 13, 2025 | globenewswire.com

Tiziana Life Sciences to Present at the Bio International Convention

June 13, 2025 | globenewswire.com

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease

May 23, 2025 | finance.yahoo.com

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease

May 23, 2025 | globenewswire.com

Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's Disease

May 15, 2025 | finance.yahoo.com

Tiziana Life Sciences' foralumab reduced neuroinflammation in Alzheimer's patient, study shows

May 15, 2025 | proactiveinvestors.com

Tiziana Life Sciences reports purchase of shares by chairman

May 12, 2025 | msn.com

Tiziana Life Sciences Announces Purchase of Shares by Chairman

May 12, 2025 | globenewswire.com

Tiziana Life Sciences reports reduced brain inflammation in Alzheimer's patient treated with nasal foralumab

May 9, 2025 | proactiveinvestors.com

Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab

May 9, 2025 | globenewswire.com

Tiziana Life Sciences’ intranasal MS candidate shows promise in open-label study

May 8, 2025 | pmlive.comP

Tiziana shares surge 21% on promising multiple sclerosis data

May 6, 2025 | proactiveinvestors.com

Tiziana reports encouraging results for nasal MS drug in early study

May 6, 2025 | proactiveinvestors.com

Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis

May 6, 2025 | globenewswire.com

Why Tiziana Life Sciences Ltd (TLSA) is Surging in 2025

April 30, 2025 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKTX, TLSA, NKTX, and LYEL Company Descriptions

Akari Therapeutics NASDAQ:AKTX

$1.13 0.00 (-0.09%)

Closing price 03:58 PM Eastern

Extended Trading

$1.14 +0.00 (+0.09%)

As of 05:16 PM Eastern

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

Lyell Immunopharma NASDAQ:LYEL

$10.28 +0.79 (+8.32%)

Closing price 04:00 PM Eastern

Extended Trading

$10.28 0.00 (0.00%)

As of 04:04 PM Eastern

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Nkarta NASDAQ:NKTX

$2.08 +0.16 (+8.33%)

Closing price 04:00 PM Eastern

Extended Trading

$2.06 -0.02 (-0.96%)

As of 07:57 PM Eastern

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Tiziana Life Sciences NASDAQ:TLSA

$1.62 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.60 -0.02 (-0.93%)

As of 07:48 PM Eastern

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time